Tetsuo Nakamura

This inventor holds 13 USPTO granted patents and 3 EPO patents. Top assignees: Immuno Japan Inc., Chugai Seiyaku Kabushiki Kaisha, Institute of Immunology Co., Ltd.. Active years: 1991-2012.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Tetsuo Nakamura. Retrieved from https://idiyas.com/inventor/tetsuo-nakamura-30f2rxjv

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 13

% Patents Active = 92.3

EPO Patents = 3 (Patent Applications = 2)

Average Co-Inventor Count = 2.3

ph-index = 8

Forward Citations = 194(Granted Patents)

Location History:

Tokyo, JP (1991 - 2012)
Bunkyo-ku, JP (2010 - 2012)

Company Filing History:

Chugai Seiyaku Kabushiki Kaisha

patents

2 out of 3

Institute of Immunology Co., Ltd.

Years Active: 1991-2012

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8263077 - Cell growth inhibitors containing anti-glypican 3 antibody (2012-09-11),

2. 8101179 - Anti-CD20 monoclonal antibody (2012-01-24),

3. 7744880 - Cell growth inhibitors containing anti-glypican 3 antibody (2010-06-29),

4. 6103485 - Non-A non-B hepatitis related nucleic acids proteins peptides antigens (2000-08-15),

5. 5972905 - Use of oligosaccharides for the treatment of pruritus cutaneus (1999-10-26),

6. 5856458 - Oligonucleotide primers, and their application for high-fidelity (1999-01-05),

7. 5766867 - Non-A, non-B hepatitis related nucleic acids, proteins, peptides, (1998-06-16),

8. 5428145 - Non-A, non-B, hepatitis virus genome, polynucleotides, polypeptides, (1995-06-27),

9. 5427909 - Oligonucleotides and determination system of HCV genotypes (1995-06-27),

10. 5176994 - Non-A, Non-B hepatitis virus genome RNA, cDNA and virus antigen protein (1993-01-05),

11. 5128334 - Analgesic and anti-inflammatory medicine (1992-07-07),

12. 5077193 - Non-A, Non-B hepatitis virus genome RNA, cDNA and virus antigen protein (1991-12-31),

13. 5019386 - Hepatitis B vaccine (1991-05-28),

Title: **Tetsuo Nakamura: Innovator in Monoclonal Antibodies and Hepatitis Research**

Introduction

Tetsuo Nakamura is a distinguished inventor based in Tokyo, Japan, known for his significant contributions to the fields of immunology and biotechnology. With a remarkable portfolio of 11 patents, Nakamura has focused on developing innovative therapeutic solutions that have the potential to impact medical treatments.

Latest Patents

Among Nakamura's latest inventions are key advancements in monoclonal antibody technology. His anti-CD20 monoclonal antibody demonstrates cell growth inhibitory activities, including apoptosis in human CD20 antigen-expressing cells. This invention details how the antibody can be incorporated into chimeric forms, fusing variable regions of the murine monoclonal antibody with constant regions of human immunoglobulin. Additionally, he has developed a humanized version of this antibody that retains critical variable region CDRs. His work also covers novel nucleic acids, proteins, peptides, and antigens related to non-A, non-B hepatitis, paving the way for diagnostic reagents in hepatitis research.

Career Highlights

Throughout his career, Tetsuo Nakamura has worked with reputable companies in the biotechnology sector. His associations with Immuno Japan Inc. and the Institute of Immunology Co., Ltd. reflect his commitment to advancing healthcare through innovative research and product development. His patents and research findings underscore his role as a leader in the development of therapeutic antibodies.

Collaborations

Nakamura has collaborated with renowned professionals in his field, including Shunji Mishiro and Hiroaki Okamoto. These collaborations have enhanced the depth of his research, contributing to breakthroughs in antibody technology and hepatitis diagnostics.

Conclusion

Tetsuo Nakamura continues to be an influential figure in the world of immunology, driving forward the understanding and treatment of diseases through his innovative inventions. His work lays the groundwork for future discoveries that could lead to significant advancements in medical science, particularly in the treatment of conditions related to hepatitis and immune disorders.

Profile summary based on public USPTO records.